HEAL Commercialization Readiness Pilot (CRP) Program: Embedded Entrepreneurs for Small Businesses in Pain Management (SB1 Clinical Trial Not Allowed)
ID: 345222Type: Posted
Overview

Buyer

National Institutes of Health (HHS-NIH11)

Award Range

$0 - $400K

Eligible Applicants

Small Businesses

Funding Category

Health

Funding Instrument

Grant

Opportunity Category

Discretionary

Cost Sharing or Matching Requirement

Yes

Original Source

https://grants.gov/search-results-detail/345222

Additional Information

http://grants.nih.gov/grants/guide/pa-files/PAR-23-069.html
Timeline
    Description

    The National Institutes of Health (NIH) has announced the HEAL Commercialization Readiness Pilot (CRP) Program, aimed at supporting small businesses in advancing pain management technologies. This funding opportunity is specifically designed for small business concerns that have previously received SBIR or STTR Phase II or IIB funding, with the goal of integrating entrepreneurial expertise into their leadership teams to enhance commercialization readiness and attract private investment. The program is particularly significant as it addresses the critical need for innovative, non-addictive pain management solutions in response to the opioid crisis. Eligible applicants can request funding of up to $400,000 over a maximum of two years, with applications due by September 5, 2025. For further inquiries, interested parties can contact NIH Grants Information at grantsinfo@nih.gov or visit the full announcement at https://grants.nih.gov/grants/guide/pa-files/PAR-23-069.html.

    Point(s) of Contact
    grantsinfo@nih.gov
    Files
    Title
    Posted
    PAR-23-069-Full-Announcement.html
    Please provide the text you would like summarized.
    PAR-23-069.html
    The Department of Health and Human Services, through the National Institutes of Health (NIH), has launched the HEAL Commercialization Readiness Pilot (CRP) Program aimed at advancing small businesses in pain management technologies. This funding opportunity is designed for small business concerns (SBCs) that have received SBIR or STTR Phase II or IIB funding, facilitating the inclusion of entrepreneurial expertise in their leadership teams to attract private investment and form industry partnerships. The program does not accept clinical trial proposals and focuses solely on enhancing commercialization readiness. Eligible applicants can request funding of up to $400,000 over a maximum of two years, with specific due dates for applications. The CRP aims to address the significant gaps in business development capabilities among SBCs, as many lack resources for non-research activities necessary for commercialization. The application process requires detailed plans for hiring business experts, establishing a partnering strategy, and demonstrating readiness for private fundraising. The program reflects NIH's commitment to combatting the opioid crisis by promoting innovative, non-addictive pain management solutions, making it a crucial initiative within the broader HEAL Initiative.
    Similar Opportunities
    HEAL Initiative: Integrative Management of Chronic Pain and Opioid Use Disorder (OUD) for Whole Recovery: Health Systems
    National Institutes of Health
    The National Institutes of Health (NIH) is announcing a funding opportunity titled "HEAL Initiative: Integrative Management of Chronic Pain and Opioid Use Disorder (OUD) for Whole Recovery: Health Systems." This initiative aims to develop strategies to enhance the sustainable and effective delivery of integrated care for individuals suffering from both chronic pain and OUD, addressing barriers at the health systems level. The importance of this opportunity lies in its focus on improving collaborative care models and implementation strategies to better manage these co-occurring conditions, which affect a significant portion of the population. Interested applicants, particularly small businesses with expertise in chronic pain management and OUD, are encouraged to prepare for the application process, with the estimated synopsis post date set for January 12, 2026, and the estimated award date anticipated for April 1, 2027. For further inquiries, potential applicants can contact Shelley Su, Ph.D., at IMPOWR@nih.gov or by phone at 301-402-3869.
    HEAL Initiative: Non-addictive Analgesic Therapeutics Development [Small Molecules and Biologics] to Treat Pain (UG3/UH3 Clinical Trial Optional)
    National Institutes of Health
    The National Institutes of Health (NIH) is offering a funding opportunity under the HEAL Initiative to support the development of non-addictive analgesic therapeutics, specifically small molecules and biologics, aimed at treating pain. The initiative seeks to accelerate the optimization and transition of promising therapeutic candidates to Phase I clinical trials, requiring applicants to demonstrate a compelling biological rationale and suitable assays for their projects. This funding is crucial for addressing the needs of over 25 million Americans suffering from chronic pain while providing alternatives to opioids. Approximately $11 million is anticipated for distribution across four awards in FY 2024, with applications due by January 24, 2024. For further inquiries, interested parties can contact NIH Grants Information at grantsinfo@nih.gov.
    HEAL Initiative: Studies to Enable Analgesic Discovery (R61/R33 - Clinical Trial Not Allowed)
    National Institutes of Health
    The National Institutes of Health (NIH) is offering a funding opportunity under the HEAL Initiative, titled "Studies to Enable Analgesic Discovery (R61/R33 - Clinical Trial Not Allowed)." This initiative aims to support early-stage translational research focused on developing and validating tests for non-opioid analgesics, including small molecules and biologics, to address the ongoing opioid crisis and improve pain management. The program anticipates a funding pool of $2.5 million, with plans to award approximately 4-5 grants in FY 2025, and applications are due by January 15, 2027. Interested applicants can find more information and application details at the NIH grants website or contact NIH Grants Information at grantsinfo@nih.gov.
    HEAL NOFO for the HEAL INTERACT Data Center
    National Institutes of Health
    The National Institutes of Health (NIH) is announcing a Notice of Funding Opportunity (NOFO) for the HEAL INTERACT Data Center, aimed at addressing musculoskeletal and peripheral pain through integrated research initiatives. This cooperative agreement seeks to fill knowledge gaps and identify novel research directions in the field, encouraging collaborative investigations among experts in pain mechanisms. While applications are not currently being solicited, potential applicants are urged to prepare meaningful collaborations and responsive projects, with an estimated synopsis post date of September 25, 2025, and a projected award date of August 3, 2026. For further inquiries, interested parties can contact Dr. Rebecca Lenzi at rebecca.lenzi@nih.gov or by phone at 301-408-7447.
    HEAL Initiative-Early-Stage Discovery of New Pain Targets Within the Understudied Druggable Proteome (R03 Clinical Trial Not Allowed)
    National Institutes of Health
    The National Institutes of Health (NIH) is inviting applications for the HEAL Initiative's funding opportunity titled "Early-Stage Discovery of New Pain Targets Within the Understudied Druggable Proteome (R03 Clinical Trial Not Allowed)." This initiative aims to support pilot projects that identify new druggable targets for pain by generating preliminary data on understudied proteins associated with pain management. The funding opportunity is particularly significant as it seeks to advance research in pain management and drug discovery, contributing to the broader goal of addressing the opioid addiction crisis. Eligible applicants can receive up to $100,000 for projects lasting one year, with applications due by July 16, 2026. For further inquiries, interested parties can contact NIH Grants Information at grantsinfo@nih.gov or visit the additional information link at https://grants.nih.gov/grants/guide/pa-files/PAR-24-197.html.
    HEAL: Translating Addiction Epidemiology, Prevention, Treatment, and Recovery Research into Practice (R61/R33 - Clinical Trial Optional)
    National Institutes of Health
    The National Institutes of Health (NIH) is set to release a Notice of Funding Opportunity (NOFO) titled "HEAL: Translating Addiction Epidemiology, Prevention, Treatment, and Recovery Research into Practice (R61/R33 - Clinical Trial Optional)" aimed at supporting research that translates addiction-related findings into practical applications to combat the opioid crisis and overdose events. This initiative seeks to identify and address factors influencing substance use and overdose deaths, focusing on developing effective, scalable interventions that integrate evidence-based practices into routine healthcare. Interested small businesses are encouraged to prepare for this opportunity, with applications expected to be solicited after the estimated synopsis post date of August 1, 2025, and closing on October 16, 2025. For further inquiries, potential applicants can contact Dr. Tisha Wiley at tisha.wiley@nih.gov or by phone at 301-594-4381.
    HEAL Initiative: Studies to Enable Analgesic Discovery (R61/R33 - Clinical Trial Not Allowed)
    National Institutes of Health
    The National Institutes of Health (NIH) is offering a funding opportunity through the HEAL Initiative aimed at supporting research for non-opioid analgesics via the R61/R33 Exploratory/Developmental Phased Award. This initiative encourages applications that focus on the early translational steps in developing novel pain treatment strategies, including the development and validation of assays and the identification of potential therapeutic agents, while explicitly prohibiting clinical trials. The funding amount is up to $350,000 per year, with a total project period not exceeding three years, and applications are due by January 15, 2027. Interested applicants can find more information and application guidelines at the NIH grants website or contact NIH Grants Information at grantsinfo@nih.gov for further inquiries.
    HEAL Initiative: Pain Management Effectiveness Research Network: Clinical Trial Planning and Implementation Cooperative Agreement (UG3/UH3 Clinical Trial Required)
    National Institutes of Health
    The National Institutes of Health (NIH) is announcing a funding opportunity for the HEAL Initiative: Pain Management Effectiveness Research Network, specifically for Clinical Trial Planning and Implementation through a Cooperative Agreement (UG3/UH3). This initiative aims to conduct large-scale, multisite clinical trials that will evaluate the efficacy of interventions designed to reduce opioid use and improve pain management across various conditions, thereby enhancing functional outcomes for patients suffering from acute to chronic pain. The program is critical in expanding evidence-based therapeutic options for pain relief, benefiting patients and their families. Interested applicants, including various eligible entities such as tribal governments and community organizations, are encouraged to prepare for this opportunity, with applications expected to be solicited starting October 15, 2025, and closing on January 5, 2026. For further inquiries, potential applicants can contact Dr. Yolanda F. Vallejo at 301-451-1751 or via email at Yolanda.Vallejo@nih.gov.
    SBIR/STTR Commercialization Readiness Pilot (CRP) Program Technical Assistance and Late Stage Development (SB1 Clinical Trial Not Allowed)
    National Institutes of Health
    The National Institutes of Health (NIH) is set to announce the SBIR/STTR Commercialization Readiness Pilot (CRP) Program, aimed at providing technical assistance and support for late-stage development of small business concerns (SBCs) that have previously received NIH SBIR or STTR Phase II or Phase IIB funding. This program is designed to facilitate the transition of these projects to commercialization by offering resources for activities such as independent study replication, IND-enabling studies, and regulatory assistance, which are typically not covered by standard Phase II or Phase IIB grants. Eligible applicants must be U.S.-based small businesses that meet specific ownership and operational criteria, with applications expected to be solicited following the reauthorization of the SBIR program. Interested parties can reach out to the NIH SEED Office at SEEDinfo@nih.gov or call 301-827-8595 for further information, with the estimated synopsis posting date set for October 1, 2025, and the application deadline anticipated for January 5, 2026.
    SBIR/STTR Commercialization Readiness Pilot (CRP) Program (Parent SB1 Clinical Trial Required)
    National Institutes of Health
    The National Institutes of Health (NIH) is preparing to announce the SBIR/STTR Commercialization Readiness Pilot (CRP) Program, aimed at supporting small business concerns (SBCs) in transitioning their previously funded SBIR and STTR Phase II and Phase IIB projects to commercialization. This program will provide additional support for technical assistance and later-stage research and development (R&D), which may include critical studies, IND-enabling studies, clinical trials, and regulatory assistance, thereby enhancing the potential for successful market entry of innovative health solutions. The solicitation for applications is expected to be published on October 1, 2025, with a closing date of January 5, 2026, and an estimated award date of June 1, 2026. Interested applicants can reach out to the NIH SEED Office at SEEDinfo@nih.gov or by phone at 301-827-8595 for further information.